Eli Lilly and WuXi AppTec scored exits from the immunotherapy developer, which has seen its shares rocket 66% since it floated.

The Novo, Pfizer and Nan Fung-backed oncology therapy developer priced an upsized offering above its range and is now valued above $1bn.

Stanford spinout Bolt Biotherapeutics has raised more than twice as much as originally planned in an offering that also provided exits for corporates Pfizer, Novo and Fan Fung.

Immunocore has raised more than $258m in an upsized offering and an additional $15m in a concurrent private placement.

The Cambrian Biopharma-backed cancer treatment developer floated above its range in an offering on the Nasdaq Global Market.

The Tencent and Baidu-backed livestreaming app saw its shares almost triple on the first day of trading and is now valued at about $160bn.

The Alphabet-backed immunotherapy developer secured nearly $588m in what was reputedly the largest ever flotation for a preclinical life sciences company.

Harvard-linked Sana brought in nearly four times as much in proceeds as originally planned and saw shares surge 40% on the first day of trading.

Virginia Tech spinout Landos Biopharma priced its shares at $16 to raise $100m and will use proceeds to advance the development of two treatments for inflammatory bowel disease.

Chishima Real Estate, M3, Miraca, Nippon Life, POC Clinical Research, Reprocell, Toho Holdings and Zenoaq have all scored exits after the cell therapy provider went public.